Target type: biologicalprocess
The chemical reactions and pathways resulting in the breakdown of a protein or peptide by hydrolysis of its peptide bonds that is mediated by the proteasome. [GOC:tb]
The proteasomal protein catabolic process is a fundamental cellular mechanism responsible for the controlled degradation of proteins. It plays a crucial role in maintaining cellular homeostasis, regulating protein levels, and eliminating damaged or misfolded proteins. This process involves a multi-step pathway, starting with the tagging of target proteins with ubiquitin molecules, followed by their delivery to the proteasome, a barrel-shaped protein complex. Within the proteasome, the tagged proteins are unfolded and broken down into short peptides. These peptides can then be further processed and recycled back into the cell, or they can be degraded further. The proteasomal protein catabolic process is highly regulated and involves numerous proteins, including ubiquitin ligases, deubiquitinases, and chaperones. It is essential for cellular function and is implicated in various diseases, including cancer and neurodegenerative disorders.'
"
| Protein | Definition | Taxonomy |
|---|---|---|
| ATP-dependent Clp protease proteolytic subunit | An ATP-dependent Clp protease proteolytic subunit that is encoded in the genome of Escherichia coli K-12. [PRO:DNx, UniProtKB:P0A6G7] | Escherichia coli K-12 |
| Proteasome subunit alpha-type 8 | A proteasome subunit alpha-type 8 that is encoded in the genome of human. [PRO:DNx, UniProtKB:Q8TAA3] | Homo sapiens (human) |
| DNA damage-binding protein 1 | A DNA damage-binding protein 1 that is encoded in the genome of human. [PRO:DNx, UniProtKB:Q16531] | Homo sapiens (human) |
| Transitional endoplasmic reticulum ATPase | A transitional endoplasmic reticulum ATPase that is encoded in the genome of human. [PRO:DNx, UniProtKB:P55072] | Homo sapiens (human) |
| Nuclear receptor subfamily 1 group D member 1 | A nuclear receptor subfamily 1 group D member 1 that is encoded in the genome of human. [PRO:DNx, UniProtKB:P20393] | Homo sapiens (human) |
| Compound | Definition | Classes | Roles |
|---|---|---|---|
| chlorpromazine | chlorpromazine : A substituted phenothiazine in which the ring nitrogen at position 10 is attached to C-3 of an N,N-dimethylpropanamine moiety. Chlorpromazine: The prototypical phenothiazine antipsychotic drug. Like the other drugs in this class chlorpromazine's antipsychotic actions are thought to be due to long-term adaptation by the brain to blocking DOPAMINE RECEPTORS. Chlorpromazine has several other actions and therapeutic uses, including as an antiemetic and in the treatment of intractable hiccup. | organochlorine compound; phenothiazines; tertiary amine | anticoronaviral agent; antiemetic; dopaminergic antagonist; EC 3.4.21.26 (prolyl oligopeptidase) inhibitor; phenothiazine antipsychotic drug |
| clotrimazole | conazole antifungal drug; imidazole antifungal drug; imidazoles; monochlorobenzenes | antiinfective agent; environmental contaminant; xenobiotic | |
| thalidomide | 2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione : A dicarboximide that is isoindole-1,3(2H)-dione in which the hydrogen attached to the nitrogen is substituted by a 2,6-dioxopiperidin-3-yl group. thalidomide : A racemate comprising equimolar amounts of R- and S-thalidomide. Thalidomide: A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppressive and anti-angiogenic activity. It inhibits release of TUMOR NECROSIS FACTOR-ALPHA from monocytes, and modulates other cytokine action. | phthalimides; piperidones | |
| pomalidomide | 3-aminophthalimidoglutarimide: structure in first source | aromatic amine; dicarboximide; isoindoles; piperidones | angiogenesis inhibitor; antineoplastic agent; immunomodulator |
| carbobenzyloxyleucyl-tyrosine chloromethyl ketone | |||
| lenalidomide | aromatic amine; dicarboximide; isoindoles; piperidones | angiogenesis inhibitor; antineoplastic agent; immunomodulator | |
| bortezomib | amino acid amide; L-phenylalanine derivative; pyrazines | antineoplastic agent; antiprotozoal drug; protease inhibitor; proteasome inhibitor | |
| sdz 283-910 | SDZ 283-910: structure in first source | ||
| benzyloxycarbonylleucyl-leucyl-leucine aldehyde | benzyloxycarbonylleucyl-leucyl-leucine aldehyde: proteasome inhibitor N-benzyloxycarbonyl-L-leucyl-L-leucyl-L-leucinal : A tripeptide that is L-leucyl-L-leucyl-L-leucine in which the C-terminal carboxy group has been reduced to the corresponding aldehyde and the N-terminal amino group is protected as its benzyloxycarbonyl derivative. | amino aldehyde; carbamate ester; tripeptide | proteasome inhibitor |
| Methylenedioxycinnamic acid | hydroxycinnamic acid | ||
| 3,4-methylenedioxy-beta-nitrostyrene | 3,4-methylenedioxy-beta-nitrostyrene: tyrosine kinase inhibitor that prevents platelet glycoprotein IIb/IIIa activation; structure in first source | ||
| 4-(4-(4-chloro-phenyl)thiazol-2-ylamino)phenol | substituted aniline | ||
| benzyloxycarbonyl-phe-ala-fluormethylketone | cathepsin B inhibitor : A cysteine protease inhibitor which inhibits cathepsin B (EC 3.4.22.1). | ||
| am 404 | anilide | ||
| lactacystin | lactam; S-substituted L-cysteine | ||
| clasto-lactacystin beta-lactone | clasto-lactacystin beta-lactone: active metabolite of lactacystin; inhibits 20 S proteasome; structure in first source | ||
| sclerotiamide | sclerotiamide: related to the paraherquamides; isolated from the sclerotia of Aspergillus sclerotiorum; structure given in first source | ||
| marizomib | marizomib: a proteasome inhibitor from a marine bacterium Salinospora; structure in first source | beta-lactone; gamma-lactam; organic heterobicyclic compound; organochlorine compound; salinosporamide | antineoplastic agent; proteasome inhibitor |
| carfilzomib | epoxide; morpholines; tetrapeptide | antineoplastic agent; proteasome inhibitor | |
| tyropeptin a | tyropeptin A: proteasome inhibitors produced by Kitasatospora sp. MK993-dF2; structure in first source | dipeptide | |
| belactosin a | belactosin A: isolated from Streptomyces; structure in first source | ||
| oprozomib | ONX 0912: antineoplastic; an orally active proteasome inhibitor; structure in first source | ||
| ixazomib | ixazomib : A glycine derivative that is the amide obtained by formal condensation of the carboxy group of N-(2,5-dichlorobenzoyl)glycine with the amino group of [(1R)-1-amino-3-methylbutyl]boronic acid. The active metabolite of ixazomib citrate, it is used in combination therapy for treatment of multiple myeloma. ixazomib: a proteasome inhibitor with antineoplastic activity; MLN2238 is the biologically active form of MLN9708; structure in first source | benzamides; boronic acids; dichlorobenzene; glycine derivative | antineoplastic agent; apoptosis inducer; drug metabolite; orphan drug; proteasome inhibitor |
| jq1 compound | carboxylic ester; organochlorine compound; tert-butyl ester; thienotriazolodiazepine | angiogenesis inhibitor; anti-inflammatory agent; antineoplastic agent; apoptosis inducer; bromodomain-containing protein 4 inhibitor; cardioprotective agent; ferroptosis inducer | |
| ML240 | ML240 : A member of the class of quinazolines that is quinazoline which is substituted at positions 2, 5 and 8 by 2-amino-1H-benzimidazol-1-yl, benzylnitrilo and methoxy groups, respectively. It is a ATP-competetive inhibitor of AAA ATPase p97, also known as valosin-containing protein (VCP). | aromatic amine; aromatic ether; benzimidazoles; primary amino compound; quinazolines; secondary amino compound | antineoplastic agent |
| gsk4112 | GSK4112: a Rev-erbalpha agonist; structure in first source | ||
| sr 8278 | SR 8278: structure in first source | ||
| sr9009 | |||
| sr9011 | SR9011: a REV-ERB agonist; structure in first source | ||
| MZ1 | organic molecular entity | ||
| ganciclovir | 2-aminopurines; oxopurine | antiinfective agent; antiviral drug |